News
AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial
AstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a pair of positive clinical trials, but the failure of a third threatens to derail
